Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A.
about
New insights into the biology of tissue factor pathway inhibitorAnimal models of hemophiliaSmall Peptides Blocking Inhibition of Factor Xa and Tissue Factor-Factor VIIa by Tissue Factor Pathway Inhibitor (TFPI)Biology of tissue factor pathway inhibitor.Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.Therapies from fucoidan; multifunctional marine polymers.Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia.Solulin increases clot stability in whole blood from humans and dogs with hemophilia.Tissue Factor Pathway Inhibitor: Multiple Anticoagulant Activities for a Single Protein.New treatments in hemophilia: insights for the clinician.Fucoidan is a novel platelet agonist for the C-type lectin-like receptor 2 (CLEC-2)Comparison of the inhibitory activities of human tissue factor pathway inhibitor (TFPI)α and TFPIβLow plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency.Correcting thrombin generation ex vivo using different haemostatic agents following cardiac surgery requiring the use of cardiopulmonary bypass.Animal models of hemophilia and related bleeding disorders.Targeting TFPI for hemophilia treatment.Recombinant factor VIII in the management of hemophilia A: current use and future promise.Cellular expression and biological activities of alternatively spliced forms of tissue factor pathway inhibitor.Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation.Molecular approaches for improved clotting factors for hemophilia.The hope and reality of long-acting hemophilia products.The future of hemostasis management.Novel therapeutic approaches for haemophilia.Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein.Longer-acting clotting factor concentrates for hemophilia.Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins.Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex.Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia.Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma1.Bioengineered factor Xa as a potential new strategy for hemophilia therapy.Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma.Novel therapies and current clinical progress in hemophilia A.The Potential Close Future of Hemophilia Treatment - Gene Therapy, TFPI Inhibition, Antithrombin Silencing, and Mimicking Factor VIII with an Engineered Antibody.
P2860
Q26865048-72630777-34DD-4F65-AAF0-8D381D110580Q27012571-1243ED6B-2016-43E5-B7CA-24A3F46EC7A5Q27680684-52D23284-6441-493B-96CE-C00E13DAD7E7Q33585249-DDDFAC07-650E-485A-A3BD-7A21F27CC85FQ34045763-2C30FAAF-8606-439B-9C64-4C02A8504565Q35534899-2DF79A4B-62F3-489C-A353-D74ED4E04565Q35844915-AB8B01D4-0D08-4140-8B47-22DFDC07C6D1Q35885322-C579A12F-EE25-4581-BA56-473EE86C1CA5Q36403196-5BEC3CAF-475C-475E-A5F8-100456F2CCCCQ36612681-0F2D2C5B-C632-4C6F-8023-AAC54AFAE3FDQ36685191-85DA1AC5-19A9-42A7-9D50-3ECCE1F89A29Q36852177-B648AD87-6DB2-492F-9E2F-03FA4A22EE47Q36948563-3B8A9734-BE72-43DF-AFD6-55542E84D929Q36956166-A62ECB3D-9ED1-4888-BCA7-0E392FFC1647Q37091290-6FA355F2-6C6B-4E6D-B3F1-689B9E729178Q37108074-0B530EB1-ABA4-40B7-9162-23139C924156Q37230340-1BD9CBF3-6671-4147-9742-69B0ECA9A9B0Q37268966-7F7CB1AE-B2E4-4F9E-AEB4-475B0ED557B0Q37276726-0B2E585C-D5B7-4019-9403-C1AFE75A5CC2Q37334700-231642AF-3C81-4AE3-B0B8-961D69ACB838Q37990479-6DD4567E-D57E-44C5-87D7-6E3925BBA612Q38056457-FC39200E-3411-4A03-BB9C-2E24372FD4DFQ38293116-4A54560F-9B4F-4593-B739-5AC726931268Q38316749-2D3A9726-4428-441E-B892-65BC1D84FED2Q38543283-1F19467B-9980-4B9D-B254-33F5A3829C8EQ39683706-CD438053-7C77-4C42-9C86-5BDAF51124AAQ42257925-2C67698E-B9F5-49FF-BFED-1E6CEC2F78F9Q42360054-E483D88A-31C4-432B-BF1D-62E27E04CDDBQ44051815-1855ACC5-9C82-4A0A-AD76-165C45098106Q45873350-66BBC3A5-7FBA-4A67-9A63-2D093AB1F82BQ45878341-5BE122DB-68B4-4267-8485-DFE42F02646EQ45879327-21B7AC69-1E22-4533-891A-B8788B063FD3Q49745450-626A0987-315F-4739-BE0E-3B41B4F4AF41Q55211396-45C7FA92-CA76-41DD-8AE9-CF50D7F331C2
P2860
Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Efficacy and safety of a new-c ...... 13, in dogs with hemophilia A.
@en
Efficacy and safety of a new-c ...... 13, in dogs with hemophilia A.
@nl
type
label
Efficacy and safety of a new-c ...... 13, in dogs with hemophilia A.
@en
Efficacy and safety of a new-c ...... 13, in dogs with hemophilia A.
@nl
prefLabel
Efficacy and safety of a new-c ...... 13, in dogs with hemophilia A.
@en
Efficacy and safety of a new-c ...... 13, in dogs with hemophilia A.
@nl
P2093
P1433
P1476
Efficacy and safety of a new-c ...... 13, in dogs with hemophilia A.
@en
P2093
Andrea Labelle
David Lillicrap
Erin Burnett
Kirk W Johnson
Sabine Knappe
Sandra Powell
Srinivasa Prasad
Tracy Keller
P304
P356
10.1182/BLOOD-2007-07-098913
P407
P577
2007-10-31T00:00:00Z